IgAN is a serious, immune-mediated, progressive disease with an average age at diagnosis of ~35 years old, leading to severe impact on quality of life2
BAFF = B-cell activating factor; APRIL = A proliferation-inducing ligand; ; TACI = transmembrane activator and calcium-modulator and cyclophilin ligand interactor.
1Cheung CK, et al. Front Nephrol 2023; 2Dillon SR, et al. Arthritis Res Ther 2010; 3Vera data on file; 4Willen D, et al. Eur J Drug Metab Pharmacokinet 2020; 5Gordon C, et al. Rheumatol Adv Pract 2019 and data on file; 6Lafayette R, et al. Kidney Int 2024; 7Lafayette R, et al. ERA 2024, abstr 812.
IgAN, also known as Berger’s disease, is a B-cell mediated kidney disease driven by the deposition of abnormal immune complexes that accumulate in the kidneys, causing inflammatory tissue damage and kidney failure1
IgAN is a serious, immune-mediated, progressive disease with an average age at diagnosis of ~35 years old, leading to severe impact on quality of life2
Up to 50% of IgAN patients progress to end-stage kidney disease within 20 years, requiring dialysis or kidney transplant3,4
Despite current standard of care with ACEi/ARBs and CKD supportive care,5 kidney function may steadily decline6
There is a high unmet medical need for safe and effective new disease-modifying treatments for IgAN that target the upstream source of disease7
ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CKD = chronic kidney disease.
1Wyatt RJ, et al. N Engl J Med 2013; 2Jarrick S, et al. J Am Soc Nephrol 2019; 3Kwon CS, et al. J Health Econ Outcomes Res 2021; 4Pitcher D, et al. Clin J Am Soc Nephrol 2023; 5KDIGO 2021; 6Cheung CK, et al. J Clin Med 2021; 7Huang X, Xu G. Front Pharmacol 2021.
Multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of ataciceptin patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression.
1Lafayette R, et al. Kidney Int 2024; 2Floege J, et al. ERA 2024, abstr 123; 3Lafayette R, et al. ERA 2024, abstr 812; 4Mean ± SE; 5Change from baseline in number of participants with hematuria at each visit divided by number with baseline hematuria. 72-week atacicept data includes participants originally randomized to any atacicept dose (25 mg, 75 mg, 150 mg) during the double-blind period in the intent-to-treat population for Gd-IgA1, hematuria, and eGFR, and week 36 per-protocol population for UPCR.
Participants who switched from placebo to atacicept showed similar results to 36-week outcomes in participants originally randomized to atacicept
For more information, contact MEDINFO@VERATX.COM
BAFF is also known as B Lymphocyte Stimulator or BLyS.
Watch this video to learn about atacicept’s mechanism of action in IgAN and 36-week results from the ORIGIN Phase 2b clinical trial of atacicept in IgAN
Multinational, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the safety and efficacy of atacicept 150 mg in adults with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression.
Currently recruiting—learn more at theORIGINiganstudy.com or clinicaltrials.gov, or contact clinicaltrials@veratx.com